Wells Fargo Reiterates Buy Rating on RYTM
Wells Fargo maintained its buy rating for RYTM, setting a target price of $155.
Key Points
- Wells Fargo reaffirmed its buy rating on RYTM, setting a price target of $155 as of June 15, 2026.
- RYTM shares were trading at $88.38, with analysts maintaining a positive outlook.
- Peers like RA Capital and BlackRock showed varied changes in their RYTM holdings recently.
Wells Fargo has reiterated its buy rating on RYTM, setting a price target of $155. This announcement came on June 15, 2026, with the stock trading at $88.38 at the time.
Other Institutional Activity in RYTM
RA Capital Management, L.P. maintained its position in RYTM with 6,666,837 shares valued at about $579.8 million. BlackRock, Inc. slightly reduced its holdings by 60,183 shares, bringing its total to 6,237,151 shares worth around $542.4 million. Baker Bros. Advisors LP held steady with 5,604,483 shares valued at $487.4 million. Primecap Management Co/CA/ trimmed its stake by 61,160 shares, ending with 3,417,509 shares valued at approximately $297.2 million. Meanwhile, Vanguard Portfolio Management LLC and Vanguard Capital Management LLC both added new positions, each holding over 2.9 million shares.
RYTM Stock Snapshot
Shares of RYTM were trading at $88.38. The stock has been seeing positive analyst sentiment, with several firms maintaining a buy rating.
Insider Buying and Selling at Rhythm Pharmaceuticals, Inc.
On May 18, 2026, Smith Hunter, the Chief Financial Officer, sold 3,000 shares and bought another 3,000 shares at an average price of $17.87. On May 15, 2026, Christopher Paul German, the Corporate Controller & CAO, executed multiple transactions including buying 4,442 shares and selling 4,643 shares at an average price of $92.21. Yann Mazabraud, EVP and Head of International, sold 12,875 shares on April 1, 2026.
Analysts Set New Price Targets
On June 15, 2026, Wells Fargo maintained its buy rating on RYTM, setting a price target of $155. Canaccord Genuity also maintained a buy rating with a $143 target on May 7, 2026. RBC Capital followed suit with a $137 target on May 6, 2026. The consensus among analysts is a buy rating, with a mean target price reflecting continued confidence in the stock.
Bottom Line
Wells Fargo's reaffirmation of a buy rating for RYTM with a $155 target underscores the positive sentiment surrounding the stock. Investors keep a close eye on such ratings as they provide insights into the stock's potential performance. It's important to note that analyst ratings are based on various factors and should be considered as part of a broader investment strategy.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.